Ancora Biotech scores $60m in round co-led by Lightspeed and SR One

Ancora Biotech will use the funding to boost the clinical development of its trio of antibody treatments.

10 June 2022•1 min read

[data-article-body-skeleton]{display:none!important}

JavaScript is required to read this article. Please enable it in your browser and reload the page.